Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (1282)	12/2/2003 2:03:23 PM
From: Ian@SI	Read Replies (2) \| Respond to of 1321

Perhaps this explains today's nice move... 1:37 (Dow Jones) Shares of QLT (QLTI), maker of the Visudyne anti-blindness drug, are higher after IMS reported U.S. sales of $17.2 million for October alone. BMO Nesbitt Burns analyst Christine Charette says that, given the strong sales, it's doubtful much inventory buildup occurred ahead of the drug's Oct. 1 price increase. She says the strong growth in U.S. Visudyne sales recently appears to be linked to increased use, and believes the company can beat her 4Q U.S. sales forecast of $46.3 million. QLTI up 9% at $18.39. (AMG)